{
  "id": 13500899,
  "title": "Bowel cancer “melted away” after immunotherapy, then stayed away",
  "url": "https://urgent.news/2026/10/10/bowel-cancer-melted-away-after-immunotherapy-then-stayed-away-13500899",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-10T18:42:35.000Z",
  "source": {
    "name": "ScienceDaily",
    "slug": "sciencedaily",
    "url": "https://www.sciencedaily.com/releases/2026/10/261007042115.htm"
  },
  "original_language": "en",
  "account": null,
  "summary": "The NEOPRISM-CRC clinical trial, led by researchers at UCL and UCLH, has shown promising results in treating a specific form of bowel cancer. Patients who received a short course of immunotherapy, pembrolizumab, prior to surgery experienced a significant reduction in tumor size and remained cancer-free for nearly three years after the treatment. This outcome is substantially better than the typical 25% relapse rate among patients who undergo standard surgery followed by chemotherapy. The study's findings suggest that this pre-surgery immunotherapy approach may offer more durable cancer control compared to traditional treatment methods. Additionally, researchers developed personalized blood tests to monitor treatment efficacy and predict patient response, potentially enabling more targeted and personalized cancer care.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "ScienceDaily Health",
        "title": "Bowel cancer “melted away” after immunotherapy, then stayed away",
        "url": "https://urgent.news/2026/10/10/bowel-cancer-melted-away-after-immunotherapy-then-stayed-away",
        "published": "2026-10-10T18:42:35.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}